EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Select your location
Local sites
Life Sciences
Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
Aging populations and chronic disease are putting pressure on health resources around the world just as scientific progress, augmented intelligence and digital data are transforming the traditional health care models. This is causing a power shift with new entrants (often not driven by profit) disrupting the incumbents.
Staying competitive and providing the personalized experience that patients demand require life sciences organizations to find new ways of working. Partnering with others to share data, medicine and resources while anticipating trends and regulatory changes will help ensure sustainability in the increasingly evidence-based, outcomes-focused sector.
We help companies across the biotechnology, pharmaceutical and medical technology fields harness this disruption by forming the right alliances, better allocating resources and building trust with customers.
Our Latest thinking
The Unstoppables: Success stories of the world’s most inspiring entrepreneurs
The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.
09 Apr 2024
Stasia Mitchell
Pulse of the MedTech Industry report 2024
2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
07 Oct 2024
Jim Welch
Why licensing deals are a powerful source of growth in life sciences
Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.
03 Oct 2024
Dr. Markus von Minden
Beyond Borders: EY Biotechnology Report 2024
New EY biotechnology report with deal, financing and other data, plus insights on AI, GLP-1 drugs, oncology breakthroughs, the VC lens and much more.
03 Jun 2024
How will you respond to clinicians sounding the alarm on unsustainable care delivery models?
The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.
16 Oct 2023
What going digital means for Takeda
Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.
01 Jul 2022
Helmut Rattenberger
How you can create value in an intelligent health ecosystem
The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.
26 May 2022
Pamela Spence
How ecosystem participation drives more value for life sciences deals
Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.
10 Jan 2022
Subin Baral
How to account for outcome-based payment arrangements in life sciences
The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.
23 Sep 2021
EY Global
How EY can help
- Read more
-
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more -
The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more - Read more
-
New EY biotechnology report with deal, financing and other data, plus insights on AI, GLP-1 drugs, oncology breakthroughs, the VC lens and much more.
Read more -
2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
Read more
Direct to your inbox
Stay up to date with our Editor's picks newsletter.